Drugs / ⁸⁹Zr-Df-IAB22M2C
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04955262 | Aug 2019 → Jun 2021 | metastatic melanoma | Nektar Therapeutics | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03107663 | Jun 2017 → Aug 2018 | Hodgkins lymphoma, metastatic malignant neoplasm | ImaginAb, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05013099 | Dec 2021 → Jul 2025 overdue | cutaneous neuroendocrine carcinoma, melanoma, non-small cell lung carcinoma, renal cell carcinoma | ImaginAb, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03802123 | Dec 2018 → Oct 2021 | metastatic neoplasm | ImaginAb, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-08-10 | ImaginAb, Inc. | Results UC Davis' new research shows how total-body PET imaging can assess the immunological response to COVID-19 infections imaginab.com ↗
UC Davis Project Scientist and lead author Dr. Negar Omidvari unveiled the first high-resolution PET image of total-body CD8+ T-cell distribution after COVID-19 infection. |
| 2019-10-07 | ImaginAb, Inc. | Results ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine imaginab.com ↗
The data from the Phase I trial reported in the paper demonstrated 89 Zr-Df-IAB22M2C was well tolerated with no immediate or delayed side effects observed. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-08-10 | ImaginAb, Inc. | UC Davis' new research shows how total-body PET imaging can assess the immunological response to COVID-19 infections imaginab.com ↗ |
| 2019-10-07 | ImaginAb, Inc. | ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine imaginab.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (89)Zr-Df-IAB22M2C | “CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of (89)Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody.” PMID 34413145 ↗ Aug 2021 |
| Known as | zirconium Zr 89 crefmirlimab berdoxam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05013099 ↗ |
| Modality | Diagnostic / imaging agent | “CD8 T cell tracer for Positron Emission Tomography (PET)” NCT03802123 ↗ |
| Route | Intravenous | “will be administered intravenously over 5-10 minutes” NCT03107663 ↗ |